KR101821455B1 - Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 - Google Patents

Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 Download PDF

Info

Publication number
KR101821455B1
KR101821455B1 KR1020150120878A KR20150120878A KR101821455B1 KR 101821455 B1 KR101821455 B1 KR 101821455B1 KR 1020150120878 A KR1020150120878 A KR 1020150120878A KR 20150120878 A KR20150120878 A KR 20150120878A KR 101821455 B1 KR101821455 B1 KR 101821455B1
Authority
KR
South Korea
Prior art keywords
awp1
gene
cancer
expression
metastasis
Prior art date
Application number
KR1020150120878A
Other languages
English (en)
Korean (ko)
Other versions
KR20170025048A (ko
Inventor
장은주
이은진
Original Assignee
울산대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 울산대학교 산학협력단 filed Critical 울산대학교 산학협력단
Priority to KR1020150120878A priority Critical patent/KR101821455B1/ko
Priority to PCT/KR2016/008612 priority patent/WO2017034173A1/fr
Publication of KR20170025048A publication Critical patent/KR20170025048A/ko
Application granted granted Critical
Publication of KR101821455B1 publication Critical patent/KR101821455B1/ko

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020150120878A 2015-08-27 2015-08-27 Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 KR101821455B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020150120878A KR101821455B1 (ko) 2015-08-27 2015-08-27 Awp1을 포함하는 암 전이 진단용 바이오마커 조성물
PCT/KR2016/008612 WO2017034173A1 (fr) 2015-08-27 2016-08-04 Composition de biomarqueur permettant de diagnostiquer des métastases cancéreuses contenant awp1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150120878A KR101821455B1 (ko) 2015-08-27 2015-08-27 Awp1을 포함하는 암 전이 진단용 바이오마커 조성물

Publications (2)

Publication Number Publication Date
KR20170025048A KR20170025048A (ko) 2017-03-08
KR101821455B1 true KR101821455B1 (ko) 2018-01-25

Family

ID=58100451

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150120878A KR101821455B1 (ko) 2015-08-27 2015-08-27 Awp1을 포함하는 암 전이 진단용 바이오마커 조성물

Country Status (2)

Country Link
KR (1) KR101821455B1 (fr)
WO (1) WO2017034173A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200015432A (ko) 2018-08-03 2020-02-12 서울대학교병원 암의 골전이 진단용 조성물 및 이를 포함하는 키트

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005170796A (ja) 2003-12-08 2005-06-30 National Institute Of Advanced Industrial & Technology タンパク質間の新規相互作用及び新規相互作用を利用した廃用性筋萎縮治療剤又は廃用性筋萎縮に係わる方法。
US20090136945A1 (en) * 2007-10-10 2009-05-28 The Regents Of The University Of Michigan Compositions and methods for assessing disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005170796A (ja) 2003-12-08 2005-06-30 National Institute Of Advanced Industrial & Technology タンパク質間の新規相互作用及び新規相互作用を利用した廃用性筋萎縮治療剤又は廃用性筋萎縮に係わる方法。
US20090136945A1 (en) * 2007-10-10 2009-05-28 The Regents Of The University Of Michigan Compositions and methods for assessing disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cloning and characterization of AWP1, a novel protein that associates with serine/threonine kinase PRK1 in vivo (Gene, (2000), 256, pp 113-121.)
The International Journal of Biochemistry & Cell Biology, (2011), 43, pp 1612-1620.
유전자 적중기술을 이용한 골다공증 병태기전 연구 (정부과제 최종보고서, (2004), pp 1-69.)
파골 전구세포의 이동 및 분화 연구를 통한 뼈질환 연구 (정부과제 최종 보고서, (2013), pp 1-15.)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200015432A (ko) 2018-08-03 2020-02-12 서울대학교병원 암의 골전이 진단용 조성물 및 이를 포함하는 키트

Also Published As

Publication number Publication date
WO2017034173A1 (fr) 2017-03-02
KR20170025048A (ko) 2017-03-08

Similar Documents

Publication Publication Date Title
Miyake et al. Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells
Shan et al. MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1
Wang et al. Muc1 promotes migration and lung metastasis of melanoma cells
JP2016518815A (ja) 転移性がんの診断、予後、および処置の方法
Chuang et al. Functional role of the long noncoding RNA X-inactive specific transcript in leiomyoma pathogenesis
Zhou et al. MicroRNA-206 attenuates glioma cell proliferation, migration, and invasion by blocking the WNT/β-catenin pathway via direct targeting of Frizzled 7 mRNA
Sun et al. RETRACTED ARTICLE: Long noncoding RNA LINC00520 accelerates progression of papillary thyroid carcinoma by serving as a competing endogenous RNA of microRNA-577 to increase Sphk2 expression
US8936906B2 (en) Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof
Gao et al. Coagulation factor 2 thrombin receptor promotes malignancy in glioma under SOX2 regulation
Yang et al. RETRACTED ARTICLE: MicroRNA-559 plays an inhibitory role in the malignant progression of glioblastoma cells by directly targeting metadherin
You et al. Hsa_circ_0063804 enhances ovarian cancer cells proliferation and resistance to cisplatin by targeting miR-1276/CLU axis
KR100856475B1 (ko) 호르몬으로 조절되는 종양에 적합한 안티센스 치료법
KR101821455B1 (ko) Awp1을 포함하는 암 전이 진단용 바이오마커 조성물
EP2436694B1 (fr) Nouvelle protéine gpcr et son utilisation
US11674184B2 (en) Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA
WO2010059706A2 (fr) Facteurs de traduction en tant que cibles de médicament anti-vieillissement
WO2015067710A2 (fr) Tyrp1, un miarn "éponge" naturel, et son utilisation dans le cadre de la prise en charge de l'agressivité du mélanome chez l'être humain
KR101776864B1 (ko) Npffr2 억제제를 유효성분으로 포함하는 암 전이 억제 및 암 치료용 조성물
US8486905B2 (en) Use of FLJ25416 gene
KR102270926B1 (ko) Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물
WO2009084668A1 (fr) Procédé d'inhibition de la prolifération de cellules cancéreuses, inhibiteur de prolifération et procédé de criblage
KR100848666B1 (ko) NF-k B의 발현을 억제하는 s i RNA
KR20230127007A (ko) Ednra 억제제를 유효성분으로 포함하는 대장암의 예방 또는 치료용 약학적 조성물
WO2014200134A1 (fr) Composition de traitement et d'inhibition de métastase du cancer pancréatique contenant un agent inhibiteur d'expression et d'activité cthrc1 en tant que substance active
WO2015162172A2 (fr) Lncarn pour la thérapie et le diagnostic de l'angiogenèse

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant